Cite
Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study
MLA
T. Yokota, et al. “Efficacy and Safety of Rebamipide Liquid for Chemoradiotherapy-Induced Oral Mucositis in Patients with Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Study.” BMC Cancer, vol. 17, no. 1, May 2017, pp. 1–8. EBSCOhost, https://doi.org/10.1186/s12885-017-3295-4.
APA
T. Yokota, T. Ogawa, S. Takahashi, K. Okami, T. Fujii, K. Tanaka, S. Iwae, I. Ota, T. Ueda, N. Monden, K. Matsuura, H. Kojima, S. Ueda, K. Sasaki, Y. Fujimoto, Y. Hasegawa, T. Beppu, H. Nishimori, S. Hirano, … M. Tahara. (2017). Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. BMC Cancer, 17(1), 1–8. https://doi.org/10.1186/s12885-017-3295-4
Chicago
T. Yokota, T. Ogawa, S. Takahashi, K. Okami, T. Fujii, K. Tanaka, S. Iwae, et al. 2017. “Efficacy and Safety of Rebamipide Liquid for Chemoradiotherapy-Induced Oral Mucositis in Patients with Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Study.” BMC Cancer 17 (1): 1–8. doi:10.1186/s12885-017-3295-4.